A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma.

2023-505079-65-00 Protocol CC-92328-MM-001 Human pharmacology (Phase I) - First administration to humans Ended

Start 1 Apr 2022 · End 19 Jun 2024 · Status Ended · 1 EU/EEA countries · 4 sites · Protocol CC-92328-MM-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 4
Countries 1
Sites 4

Multiple myeloma

Key facts

Sponsor
Celgene Corp.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
1 Apr 2022 → 19 Jun 2024
Decision date (initial)
2023-07-10
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-505079-65-00
EudraCT number
2020-005968-64
WHO UTN
U1111-1262-7139

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple myeloma

VersionLevelCodeTermSystem organ class
21.0 LLT 10028228 Multiple myeloma 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Celgene Corp.

Sponsor organisation
Celgene Corp.
Address
Route 206 And Province Line Road
City
Princeton
Postcode
08543-4000
Country
United States

Scientific contact point

Organisation
Celgene Corp.
Contact name
GSM-CT

Public contact point

Organisation
Celgene Corp.
Contact name
GSM-CT

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 2 4
Rest of world
Canada
2

Investigational sites

Spain

4 sites · Ended
Institut Catala D'oncologia
Hematology, Carretera Canyet S/n, 08916, Badalona
Clinica Universidad De Navarra
Hematology, Avenue Pio XII 36, 31008, Pamplona
Hospital Universitario De Salamanca
Hematology, Paseo De San Vicente 58-182, 37007, Salamanca
Hospital Universitario Marques De Valdecilla
Hematology, 5 Planta, Avenida Valdecilla S/n, Santander

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2022-04-01 2022-07-28 2024-01-15

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-06-30 Spain Acceptable
2023-07-10
2023-07-10
2 SUBSTANTIAL MODIFICATION SM-1 2023-11-01 Spain Acceptable
2024-01-15
2024-01-15
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-07-02 Spain Acceptable
2024-01-15
2024-07-02